var data={"title":"Propylthiouracil: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Propylthiouracil: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6864?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=propylthiouracil-drug-information\" class=\"drug drug_general\">see &quot;Propylthiouracil: Drug information&quot;</a> and <a href=\"topic.htm?path=propylthiouracil-patient-drug-information\" class=\"drug drug_patient\">see &quot;Propylthiouracil: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10163904\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Hepatotoxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Severe liver injury and acute liver failure, in some cases fatal, have been reported in patients treated with propylthiouracil. These reports of hepatic reactions include cases requiring liver transplantation in adults and pediatric patients.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Reserve propylthiouracil for patients who cannot tolerate methimazole and in whom radioactive iodine therapy or surgery are not appropriate treatments for the management of hyperthyroidism.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Pregnancy:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Because of the risk of fetal abnormalities associated with methimazole, propylthiouracil may be the treatment of choice when an antithyroid drug is indicated during or just prior to the first trimester of pregnancy.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215073\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Propyl-Thyracil</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061542\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antithyroid Agent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11444885\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Severe liver toxicity reported in pediatric patients; monitor closely.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hyperthyroidism (including born to mothers with Graves' disease):</b> Limited data available:  Oral: 5 to 10 mg/kg/day in divided doses every 8 hours; begin with low dose and adjust dosage every few days to maintain total T<sub>3</sub>, free T<sub>4</sub>, and TSH in normal range; usual duration of therapy 2 to 3 months (Cloherty, 2012). Elevated T<sub>3</sub> may be sole indicator of inadequate treatment and elevated TSH indicates excessive antithyroid treatment. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061536\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=propylthiouracil-drug-information\" class=\"drug drug_general\">see &quot;Propylthiouracil: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: </b>Adjust dosage to maintain T<sub>3</sub>, T<sub>4</sub>, and TSH in normal range; elevated T<sub>3</sub> may be sole indicator of inadequate treatment. Elevated TSH indicates excessive antithyroid treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Pediatric: <b>Note:</b> Due to reports of severe liver toxicity, propylthiouracil is not recommended for use in pediatric patients and dosing is no longer FDA-approved for pediatric patients; use should be limited to patients who have developed minor toxic reactions to methimazole and who are not candidates for surgery or radioactive iodine treatment.  If used, limit duration to short course of therapy.  Discontinue therapy if transaminases reach 2 to 3 times ULN and fail to resolve within a week of repeat testing (Bahn [ATA/AACE 2011]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Hyperthyroidism:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children: &ge;6 years and Adolescents: Limited data available [Propyl-Thyracil Prescribing Information (Canada)]:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">  Initial: 150 mg/m<sup>2</sup>/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">6 to 10 years: 50 to 150 mg/day divided every 8 hours </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">&ge;10 years: 150 to 300 mg/day divided every 8 hours </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Maintenance (once euthyroid): Dose should be individualized based on patient response: Usual dose: 50 mg twice daily </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Adult: <b>Hyperthydroidism:</b> Oral: Initial: 300 mg daily in 3 equally divided doses (~8-hour intervals); 400 mg daily in patients with severe hyperthyroidism and/or very large goiters; an occasional patient will require 600 to 900 mg daily; usual maintenance: 100 to 150 mg daily in 3 equally divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the US manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215047\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215033\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10162707\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM208533.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/+Btau8Jzc5BLV85NUiGV6877E5pNsBQZnJdW/uYroCVg==&amp;TOPIC_ID=12745\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM208533.pdf</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061546\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;\">Oral: Administer same time in relation to meals each day, either always with meals or always between meals</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132821\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 2]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends single gloving for administration of intact tablets or capsules. If manipulating tablets/capsules (eg, to prepare an oral suspension), NIOSH recommends double gloving, a protective gown, and preparation in a controlled device; if not prepared in a controlled device, respiratory and eye/face protection as well as ventilated engineering controls are recommended. NIOSH recommends double gloving, a protective gown, and (if there is a potential for vomit or spit up) eye/face protection for administration of an oral liquid/feeding tube administration (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10379683\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061545\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Adjunctive therapy in patients intolerant of methimazole to ameliorate hyperthyroidism symptoms in preparation for surgical treatment or radioactive iodine therapy (FDA approved in adults); treatment of hyperthyroidism in patients with Graves&rsquo; disease or toxic multinodular goiter intolerant of methimazole and not candidates for surgical/radiotherapy (FDA approved in adults); has also been used for treatment of neonatal hyperthyroidism (including infants born to mothers with Graves' disease) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215107\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Propylthiouracil may be confused with Purinethol [DSC] </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">PTU is an error-prone abbreviation (mistaken as mercaptopurine [Purinethol;  6-MP])</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs that have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215105\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Edema, periarteritis, vasculitis (ANCA-positive, cutaneous, leukocytoclastic)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Drowsiness, drug fever, headache, neuritis, paresthesia, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Alopecia, dermal ulcer, erythema nodosum, exfoliative dermatitis, pruritus, skin pigmentation, skin rash, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Ageusia, dysgeusia, nausea, salivary gland disease, stomach pain, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Agranulocytosis, aplastic anemia, granulocytopenia, hemorrhage, hypoprothrombinemia, leukopenia, lymphadenopathy, splenomegaly, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Acute hepatic failure, hepatitis, hepatotoxicity (idiosyncratic) (Chalasani 2014), jaundice</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Arthralgia, lupus-like syndrome, myalgia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Renal: Acute renal failure, glomerulonephritis, nephritis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Interstitial pneumonitis, pulmonary alveolar hemorrhage</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Miscellaneous: Fever</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215054\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to propylthiouracil or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Breastfeeding</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215037\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding: May cause hypoprothrombinemia and bleeding. Monitoring is recommended, especially before surgical procedures.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: May cause significant bone marrow depression; the most severe manifestation is agranulocytosis (usually occurs within first 3 months of therapy). Aplastic anemia, thrombocytopenia, and leukopenia may also occur. Use with caution in patients receiving other drugs known to cause myelosuppression (particularly agranulocytosis); discontinue if significant bone marrow suppression occurs, particularly agranulocytosis or aplastic anemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dermatologic toxicity: May occur; discontinue in the presence of exfoliative dermatitis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fever: Discontinue in the presence of unexplained fever.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: <b>[US Boxed Warning]: Severe liver injury and acute liver failure (some fatal) have been reported and have included cases requiring liver transplantation in adult and pediatric patients, including pregnant women. Reserve propylthiouracil for patients who cannot tolerate methimazole and in whom radioactive iodine therapy or surgery are not appropriate treatments for the management of hyperthyroidism. </b> Routine liver function test monitoring may not reduce risk due to unpredictable and rapid onset. Patients should be counseled to recognize and report symptoms suggestive of hepatic dysfunction (eg, anorexia, pruritus, right upper quadrant pain), especially in first 6 months of treatment, which should prompt immediate discontinuation. Discontinue therapy if transaminases are &gt;3 times the upper limit of normal or if levels elevated at the onset of therapy increase further (Ross 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypothyroidism: May cause hypothyroidism; routinely monitor TSH and free T<sub>4</sub> levels, adjust dose to maintain euthyroid state.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lupus-like syndrome: A lupus-like syndrome (including splenomegaly and vasculitis) may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Nephritis: Has been associated with nephritis and glomerulonephritis, sometimes leading to acute renal failure.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pneumonitis: Interstitial pneumonitis has been reported; discontinue if this reaction occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vasculitis: ANCA-positive vasculitis or leukocytoclastic vasculitis may occur; discontinue in patients who develop vasculitis during therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pregnancy: <b>[US Boxed Warning]: Due to the risk of fetal abnormalities associated with methimazole, propylthiouracil may be the treatment of choice when an antithyroid drug is indicated during or just prior to the first trimester of pregnancy. </b></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28185644\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">In pediatric patients, severe liver injury including hepatic failure requiring transplantation or resulting in death have been reported with propylthiouracil (most cases with doses &ge;300 mg, but has also been reported with the lower 50 mg dose). Routine liver function test monitoring may not reduce risk due to unpredictable and rapid onset. Use is not recommended and should be limited to patients who have developed minor toxic reactions to methimazole and who are not candidates for surgery or radioactive iodine treatment. If use necessary, patients and parents should be informed of risks and propylthiouracil therapy limited to a short course with close patient monitoring (baseline CBC, liver profile including LFTs, bilirubin and alkaline phosphatase recommended). Discontinue use, contact prescriber, and obtain CBC (WBC) and LFTs (transaminases) if any of the following occur:  Tiredness, nausea, anorexia, fever, pharyngitis, malaise, pruritis, rash, jaundice, light-colored stool or dark urine, joint pain, right upper quadrant pain, abdominal bloating (Bahn [ATA/AACE 2011]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299953\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215042\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12745&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: Antithyroid Agents may increase the serum concentration of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: Propylthiouracil may diminish the diagnostic effect of Macimorelin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Iodide I131: Antithyroid Agents may diminish the therapeutic effect of Sodium Iodide I131.  Management: Discontinue antithyroid therapy 3-4 days prior to sodium iodide I-131 administration.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Theophylline Derivatives: Antithyroid Agents may increase the serum concentration of Theophylline Derivatives. <b> Exceptions: </b>Dyphylline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Antithyroid Agents may diminish the anticoagulant effect of Vitamin K Antagonists. <i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215043\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215058\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Propylthiouracil has been found to readily cross the placenta. Teratogenic effects have not been observed; however, nonteratogenic adverse effects, including fetal and neonatal hypothyroidism, goiter, and hyperthyroidism, have been reported following maternal propylthiouracil use. The transfer of thyroid-stimulating immunoglobulins can stimulate the fetal thyroid in utero and transiently after delivery and may increase the risk of fetal or neonatal hyperthyroidism (De Groot 2012; Peleg 2002).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Antithyroid treatment is recommended for the control of hyperthyroidism during pregnancy (Casey 2006; De Groot 2012). Uncontrolled maternal hyperthyroidism may result in adverse neonatal outcomes (eg, prematurity, low birth weight) and adverse maternal outcomes (eg, preeclampsia, congestive heart failure, stillbirth, and abortion). To prevent adverse fetal and maternal events, normal maternal thyroid function should be maintained prior to conception and throughout pregnancy (De Groot 2012).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <b>[US Boxed Warning]: Because of the risk of fetal abnormalities associated with methimazole, propylthiouracil may be the treatment of choice when an antithyroid drug is indicated during or just prior to the first trimester of pregnancy</b>. Due to an increased risk of liver toxicity with propylthiouracil, the use of methimazole may be preferred during the second and third trimesters. If drug therapy is changed, maternal thyroid function should be monitored after 2 weeks and then every 2 to 4 weeks (De Groot 2012). Propylthiouracil, along with other medications, is used for the treatment of thyroid storm in pregnant women (ACOG 2015).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The pharmacokinetics of propylthiouracil are not changed significantly during pregnancy; however, the severity of hyperthyroidism may fluctuate throughout pregnancy (DeGroot 2012; Sitar 1979; Sitar 1982). Doses of propylthiouracil may be decreased as pregnancy progresses and discontinued weeks to months prior to delivery.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061541\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential, liver function tests, platelets, thyroid function tests (TSH, T<sub>3</sub>, T<sub>4</sub>), prothrombin time, INR</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061544\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption>Thyroid Function Tests</caption>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead>\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Lab Parameters</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Age</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Normal Range</p></th></tr></thead>\n      <tbody>\n        <tr>\n          <td rowspan=\"4\" align=\"center\">\n            <p style=\"text-indent:0em;\">T<sub>4</sub> (thyroxine) serum concentration</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1-7 days</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">10.1-20.9 mcg/dL</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">8-14 days </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">9.8-16.6 mcg/dL </p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1 month to 1 year </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">5.5-16.0 mcg/dL</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&gt;1 year </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">4.0-12.0 mcg/dL </p></td></tr>\n        <tr>\n          <td rowspan=\"6\" align=\"center\">\n            <p style=\"text-indent:0em;\">Free thyroxine index (FTI) </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1-3 days</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">9.3-26.6 </p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1-4 weeks </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">7.6-20.8 </p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1-4 months </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">7.4-17.9 </p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">4-12 months </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">5.1-14.5 </p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1-6 years </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">5.7-13.3 </p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&gt;6 years </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">4.8-14.0  </p></td></tr>\n        <tr>\n          <td rowspan=\"4\" align=\"center\">\n            <p style=\"text-indent:0em;\">T<sub>3</sub> serum concentration</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Newborns</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">100-470 ng/dL</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1-5 years </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">100-260 ng/dL </p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">5-10 years </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">90-240 ng/dL </p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">10 years to Adult </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">70-210 ng/dL </p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">T<sub>3</sub> uptake</p></td>\n          <td align=\"center\"></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">35%-45% </p></td></tr>\n        <tr>\n          <td rowspan=\"4\" align=\"center\">\n            <p style=\"text-indent:0em;\">TSH serum concentration</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Cord</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">3-22 micro international units/mL </p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1-3 days </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&lt;40 micro international units/mL </p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">3-7 days </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&lt;25 micro international units/mL </p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&gt;7 days </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0-10 micro international units/mL </p></td></tr></tbody></table>\n    </div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215036\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits the synthesis of thyroid hormones by blocking the conversion of thyroxine to triiodothyronine in peripheral tissues (does not inactivate existing thyroxine and triiodothyronine stores in circulating blood and the thyroid and does not interfere with replacement thyroid hormones).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215053\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: For significant therapeutic effects 24 to 36 hours are required; remission of hyperthyroidism usually does not occur before 4 months of continued therapy </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: 12 to 24 hours (Clark 2006) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Concentrated in the thyroid gland (Clark 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 80% to 85% (Clark 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: 53% to 88% (Clark 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: ~1 hour (Clark 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: 1 to 2 hours (Clark 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (35%; primarily as metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215052\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:0em;\">A 5 mg/mL oral suspension may be made with tablets and a 1:1 mixture of Ora-Plus and Ora-Sweet. Crush twenty 50 mg propylthiouracil tablets in a mortar and reduce to a fine powder. Add small portions of vehicle and mix to a uniform paste; mix while adding vehicle in incremental proportions to <b>almost</b> 200 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 200 mL. Label &quot;shake well&quot; and &quot;refrigerate&quot;. Stable for 91 days refrigerated (preferred) and 70 days at room temperature.</p>\n    <div class=\"reference\">Nahata MC, Pai VB, and Hipple TF, <i>Pediatric Drug Formulations</i>, 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004.</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F215057\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Propylthiouracil Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (100): $90.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038787\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Antiroid (KR);</li>\n      <li>Bingsaiyou (CN);</li>\n      <li>Lothisil (VN);</li>\n      <li>Peteyu (TH);</li>\n      <li>Procarbizol (PK);</li>\n      <li>Procil (TW);</li>\n      <li>Propycil (CH, CZ, DE, HN, HU, PT, SK, TR);</li>\n      <li>Propyl (TH);</li>\n      <li>Propylthiocil (IL);</li>\n      <li>Propylthiouracil &rdquo;Dak&rdquo; (DK);</li>\n      <li>Propyltiouracil &rdquo;Medic&rdquo; (DK);</li>\n      <li>Proracyl (FR);</li>\n      <li>Prothiucil (AT);</li>\n      <li>Prothuril (GR);</li>\n      <li>PTU (AU, IN, LK, UY, VN);</li>\n      <li>Pyroid (TH);</li>\n      <li>Thyrosan (PL);</li>\n      <li>Tiotil (EE, SE);</li>\n      <li>Tirostat (CO, EC);</li>\n      <li>Uracil (TH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists, ACOG Practice Bulletin, Clinical Management Guidelines for Obstetrician-Gynecologists, Number 37, August 2002. (Replaces Practice Bulletin Number 32, November 2001), &ldquo;Thyroid Disease in Pregnancy,&rdquo; <i>Obstet Gynecol</i>, 2002, 100(2):387-96.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propylthiouracil-pediatric-drug-information/abstract-text/12166417/pubmed\" target=\"_blank\" id=\"12166417\">12166417</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG). Practice Bulletin No. 148: Thyroid disease in pregnancy. <i>Obstet Gynecol</i>. 2015;125(4):996-1005.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propylthiouracil-pediatric-drug-information/abstract-text/25798985 /pubmed\" target=\"_blank\" id=\"25798985 \">25798985 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bahn RS, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. <i>Endocr Pract</i>. 2011;17(3):456-520.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propylthiouracil-pediatric-drug-information/abstract-text/21700562 /pubmed\" target=\"_blank\" id=\"21700562 \">21700562 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Casey BM, Dashe JS, Wells CE, et al, &quot;Subclinical Hyperthyroidism and Pregnancy Outcomes,&quot; <i>Obstet Gynecol</i>, 2006, 107(2 Pt 1):337-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propylthiouracil-pediatric-drug-information/abstract-text/16449121/pubmed\" target=\"_blank\" id=\"16449121\">16449121</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Clark SM, Saade GR, Snodgrass WR, et al, &ldquo;Pharmacokinetics and Pharmacotherapy of Thionamides in Pregnancy,&rdquo; <i>Ther Drug Monit</i>, 2006, 28(4):477-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propylthiouracil-pediatric-drug-information/abstract-text/16885714/pubmed\" target=\"_blank\" id=\"16885714\">16885714</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cooper DS, &quot;Antithyroid Drugs,&quot; <i>N Engl J Med</i>, 2005, 352(9):905-17.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propylthiouracil-pediatric-drug-information/abstract-text/15745981/pubmed\" target=\"_blank\" id=\"15745981\">15745981</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    De Groot L, Abalovich M, Alexander EK, et al, &ldquo;Management of Thyroid Dysfunction During Pregnancy and Postpartum: An Endocrine Society Clinical Practice Guideline,&rdquo; <i>J Clin Endocrinol Metab</i>, 2012, 97(8):2543-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propylthiouracil-pediatric-drug-information/abstract-text/22869843/pubmed\" target=\"_blank\" id=\"22869843\">22869843</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Diav-Citrin O and Ornoy A, &ldquo;Teratogen Update: Antithyroid Drugs &minus; Methimazole, Carbimazole, and Propylthiouracil,&rdquo; <i>Teratology</i>, 2002, 65(1):38-44.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propylthiouracil-pediatric-drug-information/abstract-text/11835230/pubmed\" target=\"_blank\" id=\"11835230\">11835230</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lee A, Moretti, ME, Collantes A, et al, &ldquo;Choice of Breastfeeding and Physicians' Advice: A Cohort Study of Women Receiving Propylthiouracil, <i>Pediatrics</i>, 2000, 106(1 Pt 1):27-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propylthiouracil-pediatric-drug-information/abstract-text/10878145/pubmed\" target=\"_blank\" id=\"10878145\">10878145</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lock DR and Sthoeger ZM, &ldquo;Severe Hepatotoxicity on Beginning Propylthiouracil Therapy,&rdquo; <i>J Clin Gastroenterol</i>, 1997, 24(4):267-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propylthiouracil-pediatric-drug-information/abstract-text/9252857/pubmed\" target=\"_blank\" id=\"9252857\">9252857</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mandel SJ and Cooper DS, &ldquo;The Use of Antithyroid Drugs in Pregnancy and Lactation,&rdquo; <i>J Clin Endocrinol Metab</i>, 2001, 86(6):2354-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propylthiouracil-pediatric-drug-information/abstract-text/11397822/pubmed\" target=\"_blank\" id=\"11397822\">11397822</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Peleg D, Cada S, Peleg A, et al, &quot;The Relationship Between Maternal Serum Thyroid-Stimulating Immunoglobulin and Fetal and Neonatal Thyrotoxicosis,&quot; <i>Obstet Gynecol</i>, 2002, 99(6):1040-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propylthiouracil-pediatric-drug-information/abstract-text/12052596/pubmed\" target=\"_blank\" id=\"12052596\">12052596</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Propylthiouracil [prescribing information]. Fort Lee, NJ: DAVA Pharmaceuticals, Inc; February 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Propyl-Thyracil (propylthiouracil) [prescribing information]. Montreal, Quebec: Paladin Labs Inc; May 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Raby C, Lagorce JF, Jambut-Absil AC, et al, &ldquo;The Mechanism of Action of Synthetic Antithyroid Drugs: Iodine Complexation During Oxidation of Iodide,&rdquo; <i>Endocrinology</i>, 1990, 126(3):1683-91. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propylthiouracil-pediatric-drug-information/abstract-text/1689656/pubmed\" target=\"_blank\" id=\"1689656\">1689656</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sitar DS, Abu-Bakare A, and Gardiner RJ, &quot;Propylthiouracil Disposition in Pregnant and Post-partum Women,&quot; <i>Pharmacology</i>, 1982, 25(1):57-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propylthiouracil-pediatric-drug-information/abstract-text/7122691/pubmed\" target=\"_blank\" id=\"7122691\">7122691</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sitar DS, Abu-Bakare A, Gardiner RJ, et al, &quot;Effect of Chronic Therapy With Propylthiouracil on its Disposition in Hyperthyroid Patients,&quot; <i>Clin Invest Med</i>, 1979, 2(2-3):93-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propylthiouracil-pediatric-drug-information/abstract-text/583267/pubmed\" target=\"_blank\" id=\"583267\">583267</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stagnaro-Green A, Abalovich M, Alexander E, et al, &quot;Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and Postpartum,&quot; <i>Thyroid</i>, 2011, 21(10):1081-125.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/propylthiouracil-pediatric-drug-information/abstract-text/21787128/pubmed\" target=\"_blank\" id=\"21787128\">21787128</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12745 Version 104.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F10163904\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F215073\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1061542\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11444885\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1061536\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F215047\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F215033\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F10162707\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1061546\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132821\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F10379683\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1061545\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F215107\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F215105\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F215054\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F215037\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F28185644\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299953\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F215042\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F215043\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F215058\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1061541\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F1061544\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F215036\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F215053\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F215052\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F215057\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038787\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12745|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=propylthiouracil-drug-information\" class=\"drug drug_general\">Propylthiouracil: Drug information</a></li><li><a href=\"topic.htm?path=propylthiouracil-patient-drug-information\" class=\"drug drug_patient\">Propylthiouracil: Patient drug information</a></li></ul></div></div>","javascript":null}